← Leaderboards
Mark A Morgan
University Of Pennsylvania
$296,244
Attributed
$296,244
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$296,244 · 2
By mechanism
M01$296,244 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Rob R Macgregor$4,980,820
- Meenhard Herlyn$50,214,821
- Ian Frank$25,757,892
- Harvey Michael Friedman$28,257,678
- Lewis A Chodosh$38,386,361
Others in their field
Top investigators on “Bryostatin”
- Paul Wender · University Of California Los Angeles$14,065,471
- Jerome A. Zack · University Of California Los Angeles$6,137,468
- George R Pettit · Arizona State University-Tempe Campus$6,116,526
- Gary E Keck · University Of Utah$5,459,045
- Steven Grant · Virginia Commonwealth University$5,152,418
- Trevor P. Castor · Aphios Corporation$5,003,731
Research focus
BryostatinClinical ResearchCombination Cancer TherapyDrug Screening /EvaluationFemaleHuman SubjectHuman Therapy EvaluationMetastasisOvary NeoplasmsPeritoneum Neoplasm
Grant awards (7)
UNTREATED EPITHELIA OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CARCINOMA$22,838
M01 · FY2005 · RR
RANDOMIZED, PHASE II EVALUATION OF BRYOSTATIN (NSC #339555)$124,146
M01 · FY2002 · RR
RANDOMIZED, PHASE II EVALUATION OF BRYOSTATIN (NSC #339555)$124,146
M01 · FY2001 · RR
RANDOMIZED, PHASE II EVALUATION OF BRYOSTATIN (NSC #339555)$0
M01 · FY2001 · RR
RANDOMIZED, PHASE II EVALUATION OF BRYOSTATIN (NSC #339555)$25,114
M01 · FY2000 · RR
RANDOMIZED, PHASE II EVALUATION OF BRYOSTATIN (NSC #339555)$0
M01 · FY2000 · RR
RANDOMIZED, PHASE II EVALUATION OF BRYOSTATIN (NSC #339555)$0
M01 · FY2000 · RR